Tumour lineage shapes BRCA-mediated phenotypes.

ABSTRACT: Mutations in BRCA1 and BRCA2 predispose individuals to certain cancers^1-3, and disease-specific screening and preventative strategies have reduced cancer mortality in affected patients^4,5. These classical tumour-suppressor genes have tumorigenic effects associated with somatic biallelic inactivation, although haploinsufficiency may also promote the formation and progression of tumours^6,7. Moreover, BRCA1/2-mutant tumours are often deficient in the repair of double-stranded DNA breaks by homologous recombination^8-13, and consequently exhibit increased therapeutic sensitivity to platinum-containing therapy and inhibitors of poly-(ADP-ribose)-polymerase (PARP)^14,15. However, the phenotypic and therapeutic relevance of mutations in BRCA1 o

SUBMITTER: Jonsson P 

PROVIDER: S-EPMC7048239 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature